Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia?

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6375-6379

  Tanik, Serhat ^a   Albayrak, Sebahattin ^a   Zengin, Kursad ^a   Borekci, Hasan ^a   Bakirtas, Hasan ^a   Imamoglu, M Abdurrahim ^a   Gurdal, Mesut ^a  

^a BOZOK UNIVERSITY   (Turkey)

Author keywords

Benign prostatic hyperplasia; Inflammation; Neutrophil lymphocyte ratio; Progression

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; CANCER STAGING; DISEASE COURSE; FOLLOW UP; HUMAN; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC;

AGED; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 84928540452     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6375     Document Type: Article

References (31)

1. Araki T, Monden K, Araki M (2013). Comparison of 7 alpha(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study. Acta Med Okayama, 67, 245-51.
2. Celikbilek M, Dogan S, Ozbakir O, et al (2013). Neutrophillymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal, 27, 72-6.
3. Cihan YB, Arslan A, Ergul MA (2013). Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev, 14, 4779-83.
4. Crawford ED, Wilson SS, McConnell JD, et al (2006). Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol, 175, 1422-6; discussion 6-7.
5. De Marzo AM, Platz EA, Sutcliffe S, et al (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7, 256-69.
6. De Nunzio C, Kramer G, Marberger M, et al (2011). The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol, 60, 106-17.
7. Di Silverio F, Gentile V, De Matteis A, et al (2003). Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol, 43, 164-75.
8. Djavan B, Eckersberger E, Espinosa G, et al (2009). Complex mechanisms in prostatic inflammatory response. Eur Urology Supplements, 8, 872-8.
9. Emberton M, Fitzpatrick JM, Rees J (2011). Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int, 107, 876-80.
10. Falahatkar S, Mokhtari G, Pourreza F, et al (2008). Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology, 72, 813-6.
11. Fibbi B, Penna G, Morelli A, et al (2010). Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl, 33, 475-88.
12. Halazun KJ, Hardy MA, Rana AA, et al (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250, 141-51.
13. Izmirli M, Arikan B, Bayazit Y, et al (2011). Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pac J Cancer Prev, 12, 731-3.
14. Kandirali E, Boran C, Serin E, et al (2007). Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology, 70, 743-7.
15. Karaman H, Karaman A, Erden A, et al (2013). Relationship between colonic polyp type and the neutrophil/lymphocyte ratio as a biomarker. Asian Pac J Cancer Prev, 14, 3159-61.
16. Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4.
17. Konwar R, Manchanda PK, Chaudhary P, et al (2010). Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population. Asian Pac J Cancer Prev, 11, 1067-72.
18. Madersbacher S, Marszalek M, Lackner J, et al (2007). The long-term outcome of medical therapy for BPH. Eur Urol, 51, 1522-33.
19. McVary KT (2006). BPH: epidemiology and comorbidities. Am J Manag Care, 12, S122-8.
20. Michel MC, Vrydag W (2006). Alpha1-, alpha2-and betaadrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 147, 88-119.
21. Mishra VC, Allen DJ, Nicolaou C, et al (2007). Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int, 100, 327-31.
22. Nunez J, Nunez E, Bodi V, et al (2008). Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol, 101, 747-52.
23. Ozden C, Ozdal OL, Guzel O, et al (2007). The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol, 39, 859-63.
24. Partin AW, Carter HB, Chan DW, et al (1990). Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol, 143, 747-52.
25. Roehrborn CG (2008). BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int, 101, 17-21.
26. Roehrborn CG, Boyle P, Bergner D, et al (1999). Serum prostatespecific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, 54, 662-9.
27. Sebastiano C, Vincenzo F, Tommaso C, et al (2012). Dietary patterns and prostatic diseases. Front Biosci, 4, 195-204.
28. SpringerBasicRoehrborn CG, Barkin J, Tubaro A, et al (2014). Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int, 113, 623-35.
29. St Sauver JL, Jacobson DJ, McGree ME, et al (2008). Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology, 71, 475-9; discussion 9.
30. Tamhane UU, Aneja S, Montgomery D, et al (2008). Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol, 102, 653-7.
31. Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4.